Roche China R&D Center Chief Scientific Officer Li Chen On Being a Pioneer in China: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Swiss-headquartered Roche, the first multinational pharmaceutical outfit to establish a research and development center in China, recently established one of its Pharma Partnering groups in Shanghai. Roche's China CSO Li Chen sat down with PharmAsia News recently to talk about how the company is approaching R&D in the region and evolving in tandem with the pharmaceutical landscape in China. Chen is also a member of the networking organization BayHelix, which links Chinese life sciences executives.
You may also be interested in...
China's Changing Drug Market In The Wake Of Essential Drugs List
SHANGHAI - As an important part of China's $850 billion healthcare reform plan, the Essential Drug List system will bring new challenges as well as opportunities for all players in China's drug supply chain
China's Changing Drug Market In The Wake Of Essential Drugs List
SHANGHAI - As an important part of China's $850 billion healthcare reform plan, the Essential Drug List system will bring new challenges as well as opportunities for all players in China's drug supply chain
Roche China R&D Center Chief Scientific Officer Li Chen On Being a Pioneer in China (An Interview, Part 2 of 2)
Chen discusses how Roche is approaching R&D differently in China and the role that China will play in the global pharmaceutical arena.